Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

TPA for ischemic stroke in patients ≥80 years.

Henriksen EH, Ljøstad U, Tveiten A, Naess H, Thomassen L, Mygland A.

Acta Neurol Scand. 2013 May;127(5):309-15. doi: 10.1111/ane.12008. Epub 2012 Sep 18.

PMID:
22988960
2.

Predictors of in-hospital mortality and the risk of symptomatic intracerebral hemorrhage after thrombolytic therapy with recombinant tissue plasminogen activator in acute ischemic stroke.

Al-Khaled M, Matthis C, Eggers J.

J Stroke Cerebrovasc Dis. 2014 Jan;23(1):7-11. doi: 10.1016/j.jstrokecerebrovasdis.2012.04.004. Epub 2012 May 11.

PMID:
22578915
3.

Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.

Mori M, Naganuma M, Okada Y, Hasegawa Y, Shiokawa Y, Nakagawara J, Furui E, Kimura K, Yamagami H, Kario K, Okuda S, Koga M, Minematsu K, Toyoda K.

Cerebrovasc Dis. 2012;34(2):140-6. doi: 10.1159/000339759. Epub 2012 Aug 1.

PMID:
22854333
4.

Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions.

Seet RC, Rabinstein AA.

Cerebrovasc Dis. 2012;34(2):106-14. doi: 10.1159/000339675. Epub 2012 Aug 1. Review.

5.

Persistence of hyperdense middle cerebral artery sign on follow-up CT scan after intravenous thrombolysis is associated with poor outcome.

Paliwal PR, Ahmad A, Shen L, Yeo LL, Loh PK, Ng KW, Chong VF, Ong BK, Venketasubramanian N, Sinha AK, Teoh HL, Bathla G, Chan BP, Sharma VK.

Cerebrovasc Dis. 2012;33(5):446-52. doi: 10.1159/000336863. Epub 2012 Mar 28.

PMID:
22456065
6.

Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke?

Hermann A, Dzialowski I, Koch R, Gahn G.

J Neurol Sci. 2009 Sep 15;284(1-2):155-7. doi: 10.1016/j.jns.2009.05.003. Epub 2009 May 26.

PMID:
19473668
7.

Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke.

Power A, Epstein D, Cohen D, Bathula R, Devine J, Kar A, Taube D, Duncan N, Ames D.

Cerebrovasc Dis. 2013;35(1):45-52. doi: 10.1159/000345071. Epub 2013 Feb 14.

PMID:
23428996
8.

THRIVE score predicts ischemic stroke outcomes and thrombolytic hemorrhage risk in VISTA.

Flint AC, Faigeles BS, Cullen SP, Kamel H, Rao VA, Gupta R, Smith WS, Bath PM, Donnan GA; VISTA Collaboration.

Stroke. 2013 Dec;44(12):3365-9. doi: 10.1161/STROKEAHA.113.002794. Epub 2013 Sep 26.

9.

Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST).

Wahlgren N, Ahmed N, Eriksson N, Aichner F, Bluhmki E, Dávalos A, Erilä T, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Köhrmann M, Larrue V, Lees KR, Machnig T, Roine RO, Toni D, Vanhooren G; Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy Investigators.

Stroke. 2008 Dec;39(12):3316-22. doi: 10.1161/STROKEAHA.107.510768. Epub 2008 Oct 16.

10.

Lipid profile, lipid-lowering medications, and intracerebral hemorrhage after tPA in get with the guidelines-stroke.

Messé SR, Pervez MA, Smith EE, Siddique KA, Hellkamp AS, Saver JL, Bhatt DL, Fonarow GC, Peterson ED, Schwamm LH.

Stroke. 2013 May;44(5):1354-9. doi: 10.1161/STROKEAHA.111.671966. Epub 2013 Mar 14.

11.

Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke.

Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, Olson DM, Hernandez AF, Peterson ED, Schwamm LH.

JAMA. 2013 Jun 19;309(23):2480-8. doi: 10.1001/jama.2013.6959.

PMID:
23780461
12.

The impact of intracranial carotid artery calcification on the development of thrombolysis-induced intracerebral hemorrhage.

Lin TC, Chao TH, Shieh Y, Lee TH, Chang YJ, Lee JD, Peng TI, Chang KC, Liou CW, Chang TY, Hung KL, Chang CH.

J Stroke Cerebrovasc Dis. 2013 Nov;22(8):e455-62. doi: 10.1016/j.jstrokecerebrovasdis.2013.05.008. Epub 2013 Jun 22.

PMID:
23800497
13.

Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants.

Matute MC, Masjuan J, Egido JA, Fuentes B, Simal P, Díaz-Otero F, Reig G, Díez-Tejedor E, Gil-Nuñez A, Vivancos J, Alonso de Leciñana M.

Cerebrovasc Dis. 2012;33(3):231-9. doi: 10.1159/000334662. Epub 2012 Jan 19.

PMID:
22261670
14.

Frequency and predictors of symptomatic intracerebral hemorrhage in patients with ischemic stroke treated with recombinant tissue plasminogen activator outside clinical trials.

Martí-Fàbregas J, Bravo Y, Cocho D, Martí-Vilalta JL, Díaz-Manera J, San Román L, Puig M, Blanco M, Castellanos M, Millán M, Roquer J, Obach V, Maestre J.

Cerebrovasc Dis. 2007;23(2-3):85-90. Epub 2006 Nov 15.

PMID:
17114877
15.
16.

Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients.

Alvarez-Sabín J, Molina CA, Montaner J, Arenillas JF, Huertas R, Ribo M, Codina A, Quintana M.

Stroke. 2003 May;34(5):1235-41. Epub 2003 Apr 3.

17.

Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke.

Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, Wang X, Zhu M, Sorensen AG, Lo EH, Kelly PJ.

Neurology. 2006 May 23;66(10):1550-5.

PMID:
16717217
18.

Is the benefit of early recanalization sustained at 3 months? A prospective cohort study.

Labiche LA, Al-Senani F, Wojner AW, Grotta JC, Malkoff M, Alexandrov AV.

Stroke. 2003 Mar;34(3):695-8. Epub 2003 Feb 13.

19.

Different doses of recombinant tissue-type plasminogen activator for acute stroke in Chinese patients.

Chao AC, Liu CK, Chen CH, Lin HJ, Liu CH, Jeng JS, Hu CJ, Chung CP, Hsu HY, Sheng WY, Hu HH; Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study Group.

Stroke. 2014 Aug;45(8):2359-65. doi: 10.1161/STROKEAHA.114.005245. Epub 2014 Jul 3.

20.

Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke-Full Dose Regimen Stroke Trial.

Adeoye O, Sucharew H, Khoury J, Vagal A, Schmit PA, Ewing I, Levine SR, Demel S, Eckerle B, Katz B, Kleindorfer D, Stettler B, Woo D, Khatri P, Broderick JP, Pancioli AM.

Stroke. 2015 Sep;46(9):2529-33. doi: 10.1161/STROKEAHA.115.010260. Epub 2015 Aug 4.

PMID:
26243231
Items per page

Supplemental Content

Write to the Help Desk